Characterization of Potent ABCG2 Inhibitor Derived from Chromone: From the Mechanism of Inhibition to Human Extracellular Vesicles for Drug Delivery

Pharmaceutics. 2023 Apr 17;15(4):1259. doi: 10.3390/pharmaceutics15041259.

Abstract

Inhibition of ABC transporters is a promising approach to overcome multidrug resistance in cancer. Herein, we report the characterization of a potent ABCG2 inhibitor, namely, chromone 4a (C4a). Molecular docking and in vitro assays using ABCG2 and P-glycoprotein (P-gp) expressing membrane vesicles of insect cells revealed that C4a interacts with both transporters, while showing selectivity toward ABCG2 using cell-based transport assays. C4a inhibited the ABCG2-mediated efflux of different substrates and molecular dynamic simulations demonstrated that C4a binds in the Ko143-binding pocket. Liposomes and extracellular vesicles (EVs) of Giardia intestinalis and human blood were used to successfully bypass the poor water solubility and delivery of C4a as assessed by inhibition of the ABCG2 function. Human blood EVs also promoted delivery of the well-known P-gp inhibitor, elacridar. Here, for the first time, we demonstrated the potential use of plasma circulating EVs for drug delivery of hydrophobic drugs targeting membrane proteins.

Keywords: ABCG2 transporter; chromones; drug delivery; extracellular vesicles; inhibitors.

Grants and funding

This research was funded by the Brazilian Research Council (CNPq, grant numbers 400953/2016-1-404286/2021-6) and Fundação Araucária-PPSUS 2020/2021 (SUS2020131000003). T.K. is financed by the iFIT (EXC2180–390900677), Fortüne initiative (NR.2613-0) and the Federal Ministry of Education and Research (BMBF) and the Baden-Württemberg Ministry of Science as part of the Excellence Strategy of the German Federal and State Governments, Germany, by means of the program TüCAD2. This work was supported by CBH-EUR-GS (ANR-17-EURE-0003) to A.B.; D.H.K. and S.V.A. were funded by the Intramural Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.